Medicamen Biotech (Small Cap - High Growth) Share Target 2025, 2026 To 2035
|
Medicamen Biotech Limited |
|||
|
Price: ₹486.60 (-1.21%) | ||
| 52 Week Low: ₹355.45 52 Week High: ₹630.00 |
|||
| Market Capital: 583.66 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Medicamen Biotech Share Price Target For 2025
- 1.1.1: Medicamen Biotech Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Medicamen Biotech Share Price Target For 2026
- 1.2.1: Medicamen Biotech Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Medicamen Biotech Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Medicamen Biotech Brief Company Overview
- 4: Medicamen Biotech Financial Performance
- 4.0.1: Is Medicamen Biotech A Good Buy For Long Term?
Medicamen Biotech, a Small Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 50.7% returns in 5-year showing 2.6% quarterly revenue growth with 4.5% profit margin, making it a High Growth stock.
To predict the Medicamen Biotech's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Medicamen Biotech Share Price Target For 2025
The line chart displays the monthly closing prices of Medicamen Biotech with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Medicamen Biotech shares in 2025, see the table below.
Medicamen Biotech Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 539.55 (+10.88%) | Price Action: Oct 2021 Low |
| 2025 Target 2 | 533.84 (+9.69%) | Price Action: Jul 2024 High |
| 2025 Target 1 | 528.25 (+8.55%) | Price Action: 07 Feb 2024 High |
| Current Price | 486.60 | Medicamen Biotech's share price as of 23 Jan 2025 |
| Stop Loss 1 | 467.05 (-4.01%) | Price Action: 18 Jun 2024 Low |
| Stop Loss 2 | 460.9 (-5.29%) | Price Action: 06 Jun 2024 Low |
| Stop Loss 3 | 456.0 (-6.29%) | Price Action: 01 Jul 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Medicamen Biotech is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹502.2 serves as the nearest technical reference point.
Historical Returns: 3-month: -9.26% | 6-month: +12.36% | 1-year: -9.68%
Medicamen Biotech Share Price Target For 2026
The line chart displays the monthly closing prices of Medicamen Biotech with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Medicamen Biotech shares in 2026, see the table below.
Medicamen Biotech Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 826.27 (+69.8%) | Price Action: Chart |
| 2026 Target 2 | 810.86 (+66.63%) | Price Action: Chart |
| 2026 Target 1 | 802.83 (+64.98%) | Fibonacci Extension Level 64.90% |
| Current Price | 486.60 | Medicamen Biotech's share price as of 23 Jan 2025 |
| Stop Loss 1 | 414.0 (-14.92%) | Price Action: Jun 2019 Low |
| Stop Loss 2 | 409.7 (-15.81%) | Price Action: 19 Mar 2024 High |
| Stop Loss 3 | 404.0 (-16.98%) | Price Action: 27 Aug 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Medicamen Biotech is currently trading at 47.8% of its 52-week range (₹355.45 - ₹630).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: -9.68% | 3-year: -39.78% | 5-year: +50.67%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Medicamen Biotech Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹486.60 | ||
| 2025 | ₹722.09 | +48.39% | ₹732.92 |
| 2026 | ₹852.97 | +18.12% | ₹865.76 |
| 2027 | ₹1,005.47 | +17.87% | ₹1,020.55 |
| 2028 | ₹1,135.64 | +12.94% | ₹1,152.67 |
| 2029 | ₹1,293.17 | +13.87% | ₹1,312.57 |
| 2030 | ₹1,516.43 | +17.26% | ₹1,539.18 |
| 2031 | ₹1,810.88 | +19.41% | ₹1,838.04 |
| 2032 | ₹2,005.68 | +10.75% | ₹2,035.77 |
| 2033 | ₹2,224.78 | +10.92% | ₹2,258.15 |
| 2034 | ₹2,587.02 | +16.28% | ₹2,625.83 |
| 2035 | ₹2,963.75 | +14.56% | ₹3,008.21 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Medicamen Biotech Brief Company Overview
Medicamen Biotech Limited: A Pharmaceutical Powerhouse Medicamen Biotech Limited, established in 1993, is a leading pharmaceutical company headquartered in India. Diverse Product Range: Medicamen Biotech offers an extensive range of products, including tablets, capsules,...
liquid and dry syrups, ointments, and creams across various therapeutic areas. Industry Reputation: With over 27 years of experience, the company has earned a reputable reputation in the pharmaceutical industry for its quality products and commitment to innovation. Commitment to Healthcare: Medicamen Biotech is dedicated to providing affordable and accessible healthcare solutions to patients in India and beyond.Medicamen Biotech Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 583.66 Crore | Market valuation of Medicamen Biotech's shares. |
| Revenue (TTM) | 180.41 Crore | Total revenue generated by Medicamen Biotech over the past twelve months. |
| Net Income (TTM) | +8.1 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +3.89% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +4.49% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+2.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-67.7% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
15.37 | Company's total debt divided by total shareholder equity. |
| Total Debt | 30.81 Crore | Sum of Medicamen Biotech's current & long-term financial obligations. |
| Total Cash | 14.78 Crore | Total amount of liquid funds available to Medicamen Biotech. |
| Beta | 1.5 | Beta is greater than 1 indicating that the Medicamen Biotech's price is more volatile than the market. |
Is Medicamen Biotech A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
